FDA Zepbound (tirzepatide) prescribing information, 2025 update official label, GI side-effect rates, discontinuation data, AKI warning
or overweight if their BMI is greater than 27 accompanied by weight-related medical problems such as high blood pressure, type 2 diabetes, or high cholesterol
[DOI] [PMC free article] [PubMed] [Google Scholar] 29.Mavropoulos A, Rigopoulou EI, Liaskos C, Bogdanos DP, Sakkas LI
CMS reinforced this stance in 2008, clarifying that even non-cosmetic weight loss agents were ineligible for Part D coverage
If you use tobacco or alcohol, your care team will talk to you about the risks and how to make changes that will help you and your baby
Our telehealth-first approach means you have 24/7 access to specialized support